Tracking Odevixibat Safety and Outcomes in PFIC Patients
Part of Digestive system clinical trials.
This study follows patients with PFIC (a rare liver disease affecting bile flow) who are taking or planning to take odevixibat (Bylvay), a medication that helps manage the condition. Researchers will track how well the medication works, any side effects, and long-term health outcomes in Chinese patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with PFIC (any type)
- Your doctor has prescribed odevixibat (Bylvay) for you
- You are starting or already taking odevixibat treatment
- You provide signed informed consent (or parent/guardian consent if under 18)
- You are not currently enrolled in another clinical trial testing odevixibat or other PFIC treatments
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is tracking how well odevixibat (Bylvay) works and how safe it is for people with progressive familial intrahepatic cholestasis (PFIC) in South Korea. It is for patients who are already prescribed this medicine by their doctor, and it monitors their progress over time.
This study tracks treatments and outcomes for people with a confirmed genetic form of PFIC, a rare liver disease. It helps doctors learn which treatments work best for each type.
This study looks at different genetic liver conditions called PFIC and follows how they progress over time. It also studies whether a procedure called biliary diversion may improve symptoms or long-term outcomes.
This study looks at the long-term safety and effects of Livmarli (maralixibat) in children with Alagille syndrome or progressive familial intrahepatic cholestasis (PFIC). It may help understand how well the medicine works over time for itching and other symptoms.
This study is following patients who are already taking Livmarli (maralixibat) for Alagille syndrome or PFIC to see how safe and effective it is over the long term.
This study follows children with biliary atresia who finished an earlier 104-week treatment study, to check how well odevixibat works over the long term and whether it remains safe. If you completed the prior study, this extension may be an option to continue monitoring and treatment.
Hear when a new Progressive Familial Intrahepatic Cholestasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.